Javascript must be enabled to continue!
Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach
View through CrossRef
(1) Background: Prostate-specific membrane antigen (PSMA) has been extensively studied in the last decade. It became a promising biological target in the diagnosis and therapy of PSMA-expressing cancer diseases. Although there are several radiolabeled PSMA inhibitors available, the search for new compounds with improved pharmacokinetic properties and simplified synthesis is still ongoing. In this study, we developed PSMA ligands with two different hybrid chelators and a modified linker. Both compounds have displayed a promising pharmacokinetic profile. (2) Methods: DATA5m.SA.KuE and AAZTA5.SA.KuE were synthesized. DATA5m.SA.KuE was labeled with gallium-68 and radiochemical yields of various amounts of precursor at different temperatures were determined. Complex stability in phosphate-buffered saline (PBS) and human serum (HS) was examined at 37 °C. Binding affinity and internalization ratio were determined in in vitro assays using PSMA-positive LNCaP cells. Tumor accumulation and biodistribution were evaluated in vivo and ex vivo using an LNCaP Balb/c nude mouse model. All experiments were conducted with PSMA-11 as reference. (3) Results: DATA5m.SA.KuE was synthesized successfully. AAZTA5.SA.KuE was synthesized and labeled according to the literature. Radiolabeling of DATA5m.SA.KuE with gallium-68 was performed in ammonium acetate buffer (1 M, pH 5.5). High radiochemical yields (>98%) were obtained with 5 nmol at 70 °C, 15 nmol at 50 °C, and 60 nmol (50 µg) at room temperature. [68Ga]Ga-DATA5m.SA.KuE was stable in human serum as well as in PBS after 120 min. PSMA binding affinities of AAZTA5.SA.KuE and DATA5m.SA.KuE were in the nanomolar range. PSMA-specific internalization ratio was comparable to PSMA-11. In vivo and ex vivo studies of [177Lu]Lu-AAZTA5.SA.KuE, [44Sc]Sc-AAZTA5.SA.KuE and [68Ga]Ga-DATA5m.SA.KuE displayed specific accumulation in the tumor along with fast clearance and reduced off-target uptake. (4) Conclusions: Both KuE-conjugates showed promising properties especially in vivo allowing for translational theranostic use.
Title: Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach
Description:
(1) Background: Prostate-specific membrane antigen (PSMA) has been extensively studied in the last decade.
It became a promising biological target in the diagnosis and therapy of PSMA-expressing cancer diseases.
Although there are several radiolabeled PSMA inhibitors available, the search for new compounds with improved pharmacokinetic properties and simplified synthesis is still ongoing.
In this study, we developed PSMA ligands with two different hybrid chelators and a modified linker.
Both compounds have displayed a promising pharmacokinetic profile.
(2) Methods: DATA5m.
SA.
KuE and AAZTA5.
SA.
KuE were synthesized.
DATA5m.
SA.
KuE was labeled with gallium-68 and radiochemical yields of various amounts of precursor at different temperatures were determined.
Complex stability in phosphate-buffered saline (PBS) and human serum (HS) was examined at 37 °C.
Binding affinity and internalization ratio were determined in in vitro assays using PSMA-positive LNCaP cells.
Tumor accumulation and biodistribution were evaluated in vivo and ex vivo using an LNCaP Balb/c nude mouse model.
All experiments were conducted with PSMA-11 as reference.
(3) Results: DATA5m.
SA.
KuE was synthesized successfully.
AAZTA5.
SA.
KuE was synthesized and labeled according to the literature.
Radiolabeling of DATA5m.
SA.
KuE with gallium-68 was performed in ammonium acetate buffer (1 M, pH 5.
5).
High radiochemical yields (>98%) were obtained with 5 nmol at 70 °C, 15 nmol at 50 °C, and 60 nmol (50 µg) at room temperature.
[68Ga]Ga-DATA5m.
SA.
KuE was stable in human serum as well as in PBS after 120 min.
PSMA binding affinities of AAZTA5.
SA.
KuE and DATA5m.
SA.
KuE were in the nanomolar range.
PSMA-specific internalization ratio was comparable to PSMA-11.
In vivo and ex vivo studies of [177Lu]Lu-AAZTA5.
SA.
KuE, [44Sc]Sc-AAZTA5.
SA.
KuE and [68Ga]Ga-DATA5m.
SA.
KuE displayed specific accumulation in the tumor along with fast clearance and reduced off-target uptake.
(4) Conclusions: Both KuE-conjugates showed promising properties especially in vivo allowing for translational theranostic use.
Related Results
Abstract B054: Phase 1 study of 61Cu-NU101 in patients with prostate cancer
Abstract B054: Phase 1 study of 61Cu-NU101 in patients with prostate cancer
Abstract
Background:
Prostate Specific Membrane Antigen (PSMA)-targeted Positron Emission Tomography (PET) has revolution...
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Abstract
Background
Differentiated thyroid carcinoma (DTC) is the most common type of thyroid cancer. Treatment with surgery, radioactive iodine (RAI), and TSH suppression is effec...
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Abstract
Background
Routine prostate-specific membrane antigen (PSMA) positron emission tomography (PET) performed for primary staging or restaging ...
68Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters
68Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters
Background
Gliomas are the most common primary central nervous system tumors, of which the malignant gliomas account for 60%–75%. The primary and secondary brain malign...
Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics
Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics
Abstract
The majority of aggressive prostate cancers overexpress the transmembrane protein prostate-specific membrane antigen (PSMA). PSMA is, therefore, an attractive ta...
In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells
In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells
Background:
New treatments combating bone and extraskeletal metastases are needed for
patients with metastatic castration-resistant prostate cancer. The majority of metastases over...
PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
Abstract
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer epithelium, making it a promising target for molecular imaging and therapy....
Data from Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies
Data from Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies
<div>Abstract<p>Targeted imaging and therapy approaches based on novel prostate-specific membrane antigen (PSMA) inhibitors have fundamentally changed the treatment reg...

